Home / Publications / Intelligence Memos / Budget 2026: Innovation Initiatives Fall Short
- Media Releases
- Intelligence Memos
- |
Budget 2026: Innovation Initiatives Fall Short
Summary:
| Citation | John Lester. 2026. Budget 2026: Innovation Initiatives Fall Short. Intelligence Memos. Toronto: C.D. Howe Institute. |
| Page Title: | Budget 2026: Innovation Initiatives Fall Short – C.D. Howe Institute |
| Article Title: | Budget 2026: Innovation Initiatives Fall Short |
| URL: | https://cdhowe.org/publication/budget-2026-innovation-initiatives-fall-short/ |
| Published Date: | November 17, 2026 |
| Accessed Date: | November 17, 2026 |
Authors
Outline
Outline
Related Topics
For all media inquiries, including requests for reports or interviews:
From: John Lester
To: Federal spending observers
Date: November 17, 2026
Re: Budget 2026: Innovation Initiatives Fall Short
The federal budget introduces three new measures to boost innovation in Canada, but their impact looks to be disappointingly small.
The budget correctly identifies the troubling outflow of ideas and talent as a key drag on Canadian innovation. Its response is more generous tax treatment of capital gains on the sale of shares in qualified small businesses. Up to $15 million in capital gains will be tax-exempt, and investors will gain greater flexibility to roll over investments without triggering a tax bill.
The exemption is implicitly targeted at innovative firms, but it would be more cost-effective and easier to administer if Ottawa limited it to firms receiving the enhanced Scientific Research and Experimental Development (SR&ED) tax credit or those that have applied for a patent. Surprisingly, the budget does not restrict eligible buyers. If the goal is to keep ideas in Canada, only Canadian buyers should qualify.
A second initiative makes some pre-production commercialization expenses eligible for the SR&ED tax incentive. This will reduce commercialization costs for both large and small firms, but it will do little to keep small firms in Canada or increase the benefits to Canada from R&D conducted here. A better policy would be to support commercialization at the production stage – and making that support conditional on remaining in Canada.
The third measure enriches the Strategic Response Fund. Originally designed to support larger-scale R&D and commercialization, the fund recently had its mandate broadened to help firms cope with US tariffs and diversify into new markets. Consequently, little of this new money is likely to support innovation.
Ottawa should implement three measures to encourage more commercialization of Canadian inventions at home.
A good first step would be to make R&D support repayable if the resulting intellectual property (IP) leaves Canada, aligning our policy with that of many OECD countries.
Ottawa should also consider Israel’s model of tying repayment to the sale price of the IP, which can cause repayments to exceed the original subsidy. Making R&D support conditionally repayable would spur more commercialization activity in Canada. It also provides an incentive to retain ownership of the IP in Canada when it is commercialized abroad, leading to more tax revenue. Repayable support would also reduce the cost of the SR&ED tax credit when firms sell their IP to foreign buyers. Moreover, it would address the concern that while foreign-controlled firms account for about 40 percent of R&D spending in Canada, few of their inventions are commercialized here. Some foreign multinationals effectively buy R&D services in Canada, hiring Canadian talent to generate IP they own and deploy globally. Because Canada captures fewer benefits from this type of R&D than when IP stays at home, the subsidy rate should be lower.
Second, shift some support from R&D to commercialization. All small firms performing R&D receive federal and provincial tax credits that lower their costs roughly 40 percent. Several thousand of these firms also receive funding from the Industrial Research Assistance Program (IRAP), raising their average subsidy rate to about 65 percent. That is excessive. Ottawa should redirect IRAP funding toward commercializing Canadian inventions, making the support repayable from future commercialization profits – or immediately upon sale, with accrued interest, to a foreign buyer.
Third, the federal government should follow through on its commitment to implement an IP sandbox as announced in the 2024 Fall Economic Statement. Taxing income from IP developed through Canadian R&D at a preferential rate would encourage both more R&D and more domestic commercialization. While an IP box would primarily benefit larger firms, the prospect of future tax relief would also encourage ambitious startups to scale up in Canada rather than sell early.
Finally, the budget announced a review of commercialization policies at federal granting councils. Federal support for publicly funded research should be conditional on a commitment to retain ownership of the resulting IP and to make reasonable efforts to commercialize it. If recipients are unwilling or unable to do so, a federal agency tasked with bringing inventions to market should assume ownership of the IP.
Innovation occurs in two stages: invention and commercialization/adoption. Canada performs well at invention, but commercialization remains a persistent weakness. Budget 2026 diagnoses the problem, but its remedies fall short.
John Lester is a Fellow-in-Residence at the C.D. Howe Institute.
To send a comment or leave feedback, email us at blog@cdhowe.org.
The views expressed here are those of the author. The C.D. Howe Institute does not take corporate positions on policy matters.
